Psoriasis Clinical Trials

Showing 661-680 of 888 trials

Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities

NCT01401452

This multicenter, post marketing observational study (PMOS) was designed to evaluate the effectiveness of adalimumab over a period of 9 months as determined by the Psoriasis Area and Severity Index (PASI) in participants with moderate to severe plaque psoriasis with distinct co-morbidities. Secondary objectives of this study were to measure changes in psychological health via the Dermatology Life Quality Index (DLQI); changes in comorbidities with respect to gender; changes in quality of life using the Short Form Health Survey (SF-36); and evaluation of Minimal Clinically Important Differences (MCID).

Moderate to Severe Plaque Psoriasis

AbbVie (prior sponsor, Abbott)246 participantsStarted Aug 2011

COMPLETEDPhase 3

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

NCT01251614

This study will compare how well adalimumab works versus methotrexate (MTX) in children with moderate to severe psoriasis in the short term. It will also study how safe and how well adalimumab works in the long term and how long disease response can be maintained after stopping therapy.

Plaque Psoriasis

AbbVie (prior sponsor, Abbott)114 participantsStarted Dec 2010

COMPLETEDPhase 3

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

NCT02203032

The purpose of this study is to evaluate the efficacy and safety of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab.

Psoriasis

Janssen Research & Development, LLC872 participantsStarted Oct 2014

Birmingham, Alabama, United States • Bakersfield, California, United States • Los Angeles, California, United States +82 more locations

Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab

Related Searches

Mechanism of Action Study for Psoriasis

LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris

Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis

Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis

A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)

LEO 32731 - A Phase I Study in Healthy Subjects

Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis

Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis

Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)

Psoriatic Arthritis Treat to Target vs. Usual Care